Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2021 | Prostate Cancer | Letter to the Editor

Authors’ reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?

Authors: Ian Alberts, Svenja Elizabeth Seide, Clemens Mingels, Karl Peter Bohn, Kuangyu Shi, Helle D Zacho, Axel Rominger, Ali Afshar-Oromieh

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2021

Excerpt

Dear Sir, …

Evangelista L, Alongi P. PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer? Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05295-2.

Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05210-9.

Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. https://doi.org/10.1007/s00259-012-2298-2.CrossRef

Alberts I, Sachpekidis C, Fech V, Rominger A, Afshar-Oromieh A. PSMA-negative prostate cancer and the continued value of choline-PET/CT. Nuklearmedizin Nucl Med. 2020;59:1. https://doi.org/10.1055/a-1044-1855.CrossRef

Iravani A, Mitchell C, Akhurst T, Sandhu S, Hofman MS, Hicks RJ. Molecular imaging of neuroendocrine differentiation of prostate cancer: a case series. Clin Genitourin Cancer. 2021. https://doi.org/10.1016/j.clgc.2021.01.008.

Michalski K, Ruf J, Goetz C, Seitz AK, Buck AK, Lapa C, et al. Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05160-8.

Khreish F, Rosar F, Kratochwil C, Giesel FL, Haberkorn U, Ezziddin S. Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. Eur J Nucl Med Mol Imaging. 2020;47:2040–1. https://doi.org/10.1007/s00259-019-04623-x.CrossRef

Alberts I, Prenosil G, Sachpekidis C, Weitzel T, Shi K, Rominger A, et al. Digital versus analogue PET in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. Eur J Nucl Med Mol Imaging. 2020;47:614–23. https://doi.org/10.1007/s00259-019-04630-y.CrossRefPubMed

Alberts I, Hünermund J-N, Prenosil G, Mingels C, Bohn KP, Viscione M, et al. Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05282-7.

10.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286–94. https://doi.org/10.1016/S1470-2045(19)30415-2.CrossRefPubMedPubMedCentral

11.

Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–5.PubMed

12.

Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014;9:e99682. https://doi.org/10.1371/journal.pone.0099682.CrossRefPubMedPubMedCentral

Title: Authors’ reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?
Authors: Ian Alberts
Svenja Elizabeth Seide
Clemens Mingels
Karl Peter Bohn
Kuangyu Shi
Helle D Zacho
Axel Rominger
Ali Afshar-Oromieh
Publication date: 01-07-2021
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05376-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Authors’ reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2021

Multi-scale imaging as an essential tool for precision medicine

COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma

Challenges and future options for the production of lutetium-177

Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas

The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study

Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT